Is immunotherapy an effective treatment for Alzheimer's disease?

被引:3
|
作者
Licastro F. [1 ]
Caruso C. [2 ]
机构
[1] Dipartimento di Patologia Sperimentale, Università di Bologna, 40126 Bologna
[2] Gruppo di Studio sull'Immunosenescenza, Dipartimento di Biopatologia e Metodologie Biomediche, Università di Palermo, 90134 Palermo
关键词
Senile Plaque; Meningoencephalitis; Passive Immunization; Initial Clinical Trial; Amyloidogenic Protein;
D O I
10.1186/1742-4933-1-3
中图分类号
学科分类号
摘要
Immunotherapy in patients with Alzheimer's disease (AD) is rapidly becoming a hot topic of modern geriatric and clinical gerontology. Current views see immunization with Aβ peptide, the amyloidogenic protein found in senile plaque of AD patient's brains, or the infusion of preformed antibody specific for human Aβ, as possible therapeutic approaches to improve the cognitive status in the disease. Animal models of the disease have provided positive results from both approaches. Thus, an initial clinical trial using immunization with human Aβ in AD patients was started, but then shortly halted because of an unusually high incidence (6%) of meningoencephalitis. A long and currently ongoing debate in the scientific community about the pro or contra of vaccination or passive immunization with Aβ in AD is thereafter started. Here, the authors would like to stress few points of concern regarding these approaches in clinical practice. © 2004 Licastro and Caruso; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [41] Immunotherapy of Alzheimer's disease challenges and opportunities
    Nitsch, Roger
    Hock, Christoph
    NEUROBIOLOGY OF AGING, 2008, 29 : S19 - S19
  • [42] Active immunotherapy options for Alzheimer's disease
    Winblad, Bengt
    Graf, Ana
    Riviere, Marie-Emmanuelle
    Andreasen, Niels
    Ryan, J. Michael
    ALZHEIMERS RESEARCH & THERAPY, 2014, 6 (01):
  • [43] Intravenous immunoglobulin and Alzheimer's disease immunotherapy
    Solomon, Beka
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2007, 9 (01) : 79 - 85
  • [44] Immunotherapy in Alzheimer's disease: is Aβ the right target?
    Boche, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S130 - S130
  • [45] Gut Microbiota and Immunotherapy for Alzheimer's Disease
    Dai, Chun-Ling
    Liu, Fei
    Iqbal, Khalid
    Gong, Cheng-Xin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [46] Alternative Aβ Immunotherapy Approaches for Alzheimer's Disease
    Town, Terrence
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (02) : 114 - 127
  • [47] Active immunotherapy options for Alzheimer’s disease
    Bengt Winblad
    Ana Graf
    Marie-Emmanuelle Riviere
    Niels Andreasen
    J Michael Ryan
    Alzheimer's Research & Therapy, 6
  • [48] Amyloid-β Immunotherapy for Alzheimer's Disease
    Fu, H. J.
    Liu, B.
    Frost, J. L.
    Lemere, C. A.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (02) : 197 - 206
  • [49] Immunotherapy for Alzheimer's disease: will vaccination work?
    Dodart, JC
    Bales, KR
    Paul, SM
    TRENDS IN MOLECULAR MEDICINE, 2003, 9 (03) : 85 - 87
  • [50] Erratum: Immunology and immunotherapy of Alzheimer's disease
    Howard L. Weiner
    Dan Frenkel
    Nature Reviews Immunology, 2006, 6 : 490 - 490